| Literature DB >> 35647144 |
Jing Zhou1, Da-Xue Li1, Han Gao1, Xin-Liang Su2.
Abstract
BACKGROUND: Lymph node metastasis (LNM) of papillary thyroid carcinoma (PTC) has a certain regularity and occurs first to the central lymph node and then to the lateral lymph node. The pathway of PTC LNM can guide surgical prophylactic lymph node dissection (LND) for clinical surgeons. AIM: To investigate the relationship between subgroups of central LNM and lateral LNM in unilateral clinically node-negative PTC (cN0-PTC).Entities:
Keywords: Clinically node-negative; Lymph node metastasis; Papillary thyroid carcinoma; Prelaryngeal; Prophylactic lymph node dissection
Year: 2022 PMID: 35647144 PMCID: PMC9100740 DOI: 10.12998/wjcc.v10.i12.3709
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.534
Figure 1Flow diagram of patient selection. ELN: Enlarged lymph nodes; PTC: Papillary thyroid carcinoma; cN0: Clinically node-negative.
Clinicopathological characteristics and univariate analysis of lymph node metastasis in ipsilateral level-II, level-III, level-IV and lateral lymph nodes
|
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| Age (yr) | < 55 | 147 (81.2) | 169 (81.6) | 0.914 | 59 (76.6) | 257 (82.6) | 0.224 | 101 (80.2) | 215 (82.1) | 0.652 | 87 (87.3) | 229 (80.6) | 0.498 |
| ≥ 55 | 34 (18.8) | 38 (18.4) | 18 (23.4) | 54 (17.4) | 25 (19.8) | 47 (17.9) | 17 (16.3) | 55 (19.4) | |||||
| Sex | Female | 118 (65.2) | 154 (74.4) | 0.048 | 44 (57.1) | 228 (73.3) | 0.006 | 85 (67.5) | 187 (71.4) | 0.430 | 70 (67.3) | 202 (71.1) | 0.467 |
| Male | 63 (34.8) | 53 (25.6) | 33 (42.9) | 83 (26.7) | 41 (32.5) | 75 (28.6) | 34 (32.7) | 82 (28.9) | |||||
| Primary tumor size | > 2 cm | 44 (24.3) | 21 (10.1) | < 0.001 | 24 (31.2) | 41 (13.2) | < 0.001 | 32 (25.4) | 33 (12.6) | 0.002 | 29 (27.9) | 36 (12.7) | < 0.001 |
| ≤ 2 cm | 137 (75.7) | 186 (89.9) | 53 (68.8) | 270 (86.8) | 94 (74.6) | 229 (87.4) | 75 (72.1) | 248 (873) | |||||
| Tumor location | UP | 57 (31.5) | 45 (21.7) | 0.029 | 31 (40.3) | 71 (22.8) | 0.002 | 38 (30.2) | 64 (24.4) | 0.230 | 28 (26.9) | 74 (26.1) | 0.864 |
| Non-UP | 124 (68.5) | 162 (78.3) | 46 (59.7) | 240 (77.2) | 88 (69.8) | 198 (75.6) | 76 (73.1) | 210 (73.9) | |||||
| Multifocality | Yes | 27 (14.9) | 21 (10.1) | 0.154 | 15 (19.5) | 33 (10.6) | 0.034 | 19 (15.1) | 29 (11.1) | 0.261 | 17 (16.3) | 31 (10.9) | 0.150 |
| No | 154 (85.1) | 186 (89.9) | 62 (80.5) | 278 (89.4) | 107 (84.9) | 233 (88.91) | 87 (83.7) | 253 (89.1) | |||||
| ETE | Yes | 78 (43.1) | 58 (28.0) | 0.002 | 38 (49.4) | 98 (31.5) | 0.003 | 54 (42.9) | 82 (31.3) | 0.025 | 52 (50.01) | 84 (29.6) | < 0.001 |
| No | 103 (56.9) | 149 (72.0) | 39 (50.6) | 213 (68.5) | 72 (57.1) | 180 (68.7) | 52 (50.0) | 200 (70.4) | |||||
| HT | Yes | 36 (19.9) | 44 (21.3) | 0.740 | 11 (14.3) | 69 (22.2) | 0.125 | 28 (22.2) | 52 (19.8) | 0.344 | 21 (20.2) | 59 (20.8) | 0.900 |
| No | 145 (80.1) | 163 (78.7) | 66 (85.7) | 242 (77.8) | 88 (77.8) | 210 (80.2) | 83 (79.8) | 225 (79.2) | |||||
| CLNM | 0 | 17 (9.4) | 86 (41.5) | < 0.001 | 10 (13.0) | 93 (29.9) | < 0.001 | 14 (11.1) | 89 (34.0) | < 0.001 | 6 (5.8) | 97 (34.2) | < 0.001 |
| 1-2 | 45 (24.9) | 65 (31.4) | 18 (23.4) | 92 (29.6) | 30 (23.8) | 80 (30.5) | 22 (21.2) | 88 (31.0) | |||||
| ≥ 3 | 119 (65.7) | 56 (27.1) | 49 (63.6) | 126 (40.5) | 82 (65.1) | 93 (35.5) | 76 (73.1) | 99 (34.9) | |||||
| Prelaryngeal LNM | 0 | 113 (62.4) | 180 (87.0) | < 0.001 | 44 (57.1) | 249 (80.1) | < 0.001 | 82 (65.1) | 21 (80.5) | 0.001 | 66 (63.5) | 37 (79.9) | < 0.001 |
| 1-2 | 62 (34.3) | 25 (12.1) | 29 (37.7) | 58 (18.6) | 38 (30.2) | 49 (18.7) | 36 (34.6) | 51 (18.0) | |||||
| ≥ 3 | 6 (3.30) | 2 (1.00) | 4 (5.2) | 4 (1.3) | 6 (4.8) | 2 (0.8) | 2 (1.9) | 6 (2.1) | |||||
| Pretracheal LNM | 0 | 65 (35.9) | 134 (64.7) | < 0.001 | 32 (41.6) | 167 (53.7) | 0.121 | 41 (32.5) | 158 (60.3) | < 0.001 | 33 (31.7) | 166 (58.5) | 0.002 |
| 1-2 | 60 (29.0) | 74 (40.9) | 30 (39.0) | 104 (33.4) | 51 (40.5) | 83 (31.7) | 47 (45.2) | 87 (30.6) | |||||
| ≥ 3 | 42 (23.2) | 13 (6.3) | 15 (19.5) | 40 (12.9) | 34 (27.0) | 21 (8.0) | 24 (23.1) | 31 (10.9) | |||||
| Ipsilateral paratracheal LNM | 0 | 46 (25.4) | 121 (58.5) | < 0.001 | 20 (26.0) | 147 (47.3) | < 0.001 | 36 (28.6) | 131 (50.0) | < 0.001 | 20 (19.2) | 147 (51.8) | < 0.001 |
| 1-2 | 73 (40.3) | 64 (30.9) | 26 (33.8) | 111 (35.7) | 42 (33.3) | 95 (36.3) | 45 (43.3) | 92 (32.4) | |||||
| ≥ 3 | 62 (34.3) | 22 (10.6) | 31 (40.3) | 53 (17.0) | 48 (38.1) | 36 (13.7) | 39 (37.5) | 45 (15.8) | |||||
HT: Hashimoto’s thyroid; PTC: Papillary carcinoma; ETE: Extrathyroid extension; CLNM: Central lymph node metastasis; LNM: Lymph node metastasis; UP: Tumors located in the upper lobe of the thyroid gland; Non-UP: Tumors located in the middle lobe, lower lobe, isthmus and whole.
Optimal scale regression analysis of lateral lymph node metastasis
|
|
|
|
|
|
|
|
| |
|
|
| |||||||
| Sex | 0.007 | 0.028 | 1 | 0.058 | 0.809 | 0.911 | 0.911 | 0.003 |
| Primary tumor size | 0.132 | 0.045 | 1 | 8.477 | 0.004 | 0.958 | 0.956 | 0.104 |
| Tumor location | 0.119 | 0.044 | 1 | 7.449 | 0.007 | 0.974 | 0.975 | 0.055 |
| ETE | 0.076 | 0.043 | 1 | 3.153 | 0.077 | 0.959 | 0.959 | 0.049 |
| Prelaryngeal LNM | 0.142 | 0.049 | 1 | 8.338 | 0.004 | 0.879 | 0.871 | 0.168 |
| Pretracheal LNM | 0.197 | 0.051 | 1 | 14.773 | 0.000 | 0.836 | 0.831 | 0.260 |
| Ipsilateral paratracheal LNM | 0.239 | 0.049 | 1 | 23.330 | 0.000 | 0.794 | 0.798 | 0.382 |
PTC: Papillary carcinoma; ETE: Extrathyroid extension; LNM: Lymph node metastasis.
Optimal scale regression analysis of ipsilateral level-II lymph node metastasis
|
|
|
|
|
|
|
|
| |
|
|
| |||||||
| Sex | 0.119 | 0.053 | 1 | 5.029 | 0.026 | 0.913 | 0.913 | 0.122 |
| Primary tumor size | 0.153 | 0.058 | 1 | 7.033 | 0.008 | 0.954 | 0.954 | 0.213 |
| Tumor location | 0.150 | 0.055 | 1 | 7.298 | 0.007 | 0.984 | 0.984 | 0.172 |
| Multifocality | 0.048 | 0.042 | 1 | 1.321 | 0.251 | 0.963 | 0.963 | 0.038 |
| ETE | 0.101 | 0.051 | 1 | 4.005 | 0.046 | 0.964 | 0.964 | 0.110 |
| Prelaryngeal LNM | 0.142 | 0.060 | 1 | 5.668 | 0.004 | 0.907 | 0.906 | 0.227 |
| Ipsilateral paratracheal LNM | 0.239 | 0.047 | 1 | 3.319 | 0.069 | 0.859 | 0.859 | 0.119 |
ETE: Extrathyroid extension; LNM: Lymph node metastasis.
Optimal scale regression analysis of ipsilateral level-III lymph node metastasis
|
|
|
|
|
|
|
|
| |
|
|
| |||||||
| Primary tumor size | 0.121 | 0.050 | 1 | 5.833 | 0.016 | 0.968 | 0.961 | 0.120 |
| ETE | 0.051 | 0.042 | 1 | 1.528 | 0.217 | 0.965 | 0.963 | 0.036 |
| Prelaryngeal LNM | 0.079 | 0.049 | 1 | 2.569 | 0.078 | 0.935 | 0.876 | 0.084 |
| Pretracheal LNM | 0.216 | 0.054 | 1 | 16.140 | 0.000 | 0.874 | 0.849 | 0.408 |
| Ipsilateral paratracheal LNM | 0.200 | 0.056 | 1 | 12.686 | 0.000 | 0.905 | 0.836 | 0.351 |
ETE: Extrathyroid extension; LNM: Lymph node metastasis.
Optimal scale regression analysis of ipsilateral level-IV lymph node metastasis
|
|
|
|
|
|
|
|
| |
|
|
| |||||||
| Primary tumor size | 0.150 | 0.051 | 1 | 8.730 | 0.003 | 0.975 | 0.961 | 0.164 |
| ETE | -0.127 | 0.052 | 1 | 5.884 | 0.016 | 0.962 | 0.963 | 0.146 |
| Prelaryngeal LNM | -0.071 | 0.046 | 1 | 2.357 | 0.126 | 0.973 | 0.876 | 0.003 |
| Pretracheal LNM | 0.149 | 0.055 | 1 | 7.415 | 0.001 | 0.884 | 0.849 | 0.216 |
| Ipsilateral paratracheal LNM | 0.251 | 0.049 | 1 | 26.079 | 0.000 | 0.889 | 0.846 | 0.472 |
ETE: Extrathyroid extension; LNM: Lymph node metastasis.